title: CD70: An emerging target in cancer immunotherapy.
abstract: Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating cancer immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies.
authors.affiliation: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium. Electronic address: julie.jacobs@uantwerpen.be.
authors.forename: J
authors.initials: J
authors.lastname: Jacobs
authors.affiliation: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
authors.forename: V
authors.initials: V
authors.lastname: Deschoolmeester
authors.affiliation: Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Zwaenepoel
authors.affiliation: Department of Oncology, Antwerp University Hospital, Edegem, Belgium; Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Rolfo
authors.affiliation: arGEN-X BVBA, Ghent, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Silence
authors.affiliation: Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Rottey
authors.affiliation: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Lardon
authors.affiliation: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Edegem, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Smits
authors.affiliation: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Pauwels
mesh_terms: D000818:Animals; D053282:CD27 Ligand / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D053282:CD27 Ligand; C505771:CD70 protein, human
keywords: CD27; CD70; Cancer immunotherapy; Combination therapy